Palmar plantar erythrodysesthesia medical therapy: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Based on the severity of the condition, PPE can be managed by reducing the dose of chemotherapy, interruption of the agents, or switching to alternative antineoplastic chemotherapy which are less causative of PPE.<ref name="pmid17101468">{{cite journal| author=Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P| title=The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. | journal=Eur J Dermatol | year= 2006 | volume= 16 | issue= 5 | pages= 494-9 | pmid=17101468 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17101468 }}</ref> | Based on the severity of the condition, PPE can be managed by reducing the dose of chemotherapy, interruption of the agents, or switching to alternative antineoplastic chemotherapy which are less causative of PPE.<ref name="pmid17101468">{{cite journal| author=Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P| title=The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. | journal=Eur J Dermatol | year= 2006 | volume= 16 | issue= 5 | pages= 494-9 | pmid=17101468 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17101468 }}</ref> | ||
The only method shown to effectively manage PPE are dose reduction and treatment suspension. Other supportive measure is also important to reduce pain and prevent secondary infection. Many different treatment strategies have been tested in case reports and retrospective studies, among which pyridoxine and COX-2 inhibitors are the most anticipated.<ref name="pmid17022868">{{cite journal| author=Gressett SM, Stanford BL, Hardwicke F| title=Management of hand-foot syndrome induced by capecitabine. | journal=J Oncol Pharm Pract | year= 2006 | volume= 12 | issue= 3 | pages= 131-41 | pmid=17022868 | doi=10.1177/1078155206069242 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17022868 }}</ref> | |||
==Medical therapy== | ==Medical therapy== | ||
Revision as of 13:20, 14 October 2018
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia medical therapy On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia medical therapy |
|
Palmar plantar erythrodysesthesia medical therapy in the news |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Based on the severity of the condition, PPE can be managed by reducing the dose of chemotherapy, interruption of the agents, or switching to alternative antineoplastic chemotherapy which are less causative of PPE.[1]
The only method shown to effectively manage PPE are dose reduction and treatment suspension. Other supportive measure is also important to reduce pain and prevent secondary infection. Many different treatment strategies have been tested in case reports and retrospective studies, among which pyridoxine and COX-2 inhibitors are the most anticipated.[2]
Medical therapy
The goal is to continue chemotherapy while reducing symptoms of PPE. Symptomatic treatment includes pyridoxine, wound care, elevation, and pain medication (Vukelja et al 1993). Corticosteroids have also shown some efficacy in relieving symptoms.
References
- ↑ Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P (2006). "The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy". Eur J Dermatol. 16 (5): 494–9. PMID 17101468.
- ↑ Gressett SM, Stanford BL, Hardwicke F (2006). "Management of hand-foot syndrome induced by capecitabine". J Oncol Pharm Pract. 12 (3): 131–41. doi:10.1177/1078155206069242. PMID 17022868.